Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-06-10

FDA Approved: MAVYRET — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for MAVYRET (glecaprevir and pibrentasvir) submitted by AbbVie, potentially updating its labeling for additional use…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mavyret (glecaprevir/pibrentasvir)

Snippet

SUPPL AP for MAVYRET (GLECAPREVIR AND PIBRENTASVIR)